Addex Therapeutics Income Statement

Financials in millions CHF. Fiscal year is January - December.

Millions CHF. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Operating Revenue	0.03	0.4	1.61	1.42	2.92	3.61
Other Revenue	0.13	0.01	0	0.02	0.24	0.27
Revenue	0.16	0.41	1.62	1.44	3.15	3.88
Revenue Growth (YoY)	-71.81%	-74.64%	11.92%	-54.18%	-18.71%	36.90%
Cost of Revenue	0.68	0.85	1.19	8.23	12.82	10.37
Gross Profit	-0.53	-0.44	0.43	-6.78	-9.67	-6.49
Selling, General & Admin	1.96	2.31	2.67	3.76	5.84	5.75
Operating Expenses	1.96	2.31	2.67	3.76	5.84	5.75
Operating Income	-2.48	-2.76	-2.24	-10.54	-15.51	-12.24
Interest Expense	-0	-0	-0	-0.03	-0.06	-0.07
Interest & Investment Income	-	0.01	0.06	0.03	0.01	0.04
Earnings From Equity Investments	-3.73	-2.18	-	-	-	-
Currency Exchange Gain (Loss)	0.02	0.02	-0.32	-0.26	0.21	-0.58
EBT Excluding Unusual Items	-6.2	-4.91	-2.5	-10.8	-15.35	-12.86
Pretax Income	-6.2	-4.91	-2.5	-10.8	-15.35	-12.86
Earnings From Continuing Operations	-6.2	-4.91	-2.5	-10.8	-15.35	-12.86
Earnings From Discontinued Operations	0.1	11.97	-8.06	-10	-	-
Net Income	-6.1	7.06	-10.56	-20.8	-15.35	-12.86
Net Income to Common	-6.1	7.06	-10.56	-20.8	-15.35	-12.86
Shares Outstanding (Basic)	102	98	74	45	34	27
Shares Outstanding (Diluted)	102	98	74	45	34	27
Shares Change (YoY)	7.75%	32.04%	64.45%	32.43%	27.88%	0.96%
EPS (Basic)	-0.06	0.07	-0.14	-0.46	-0.45	-0.48
EPS (Diluted)	-0.06	0.07	-0.14	-0.46	-0.45	-0.48
Free Cash Flow	-1.58	-5.37	-8	-16.44	-14.74	-12.24
Free Cash Flow Per Share	-0.01	-0.06	-0.11	-0.36	-0.43	-0.46
Gross Margin	-	-108.35%	26.62%	-	-	-167.41%
Operating Margin	-1564.90%	-671.94%	-138.70%	-729.50%	-491.74%	-315.62%
Profit Margin	-3845.76%	1720.75%	-652.75%	-1439.78%	-486.85%	-331.48%
Free Cash Flow Margin	-993.65%	-1310.80%	-494.64%	-1137.59%	-467.34%	-315.52%
EBITDA	-2.46	-2.56	-2.23	-10.53	-15.16	-11.86
EBITDA Margin	-	-	-137.97%	-	-	-
D&A For EBITDA	0.02	0.19	0.01	0.01	0.35	0.38
EBIT	-2.48	-2.76	-2.24	-10.54	-15.51	-12.24
EBIT Margin	-	-	-138.70%	-	-	-

Updated Dec 4, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q